Finance

Beta
Lists
RGEN:NASDAQ
Repligen Corp
$126.55
+3.96%
(+4.82) 1D
$126.55
0.00% (0.00)
After hours
Closed: Jun 4, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RGEN...
Open
$121.80
High
$128.46
Low
$121.73
Mkt. cap
7.14B
Avg. vol.
1.28M
Volume
0.00
P/E ratio
138.88
52-wk high
$175.77
52-wk low
$100.99
EPS
$0.91
Beta
1.09
Shares outstanding
56.41M
No. of employees
2K
Open
$121.80
High
$128.46
Low
$121.73
Mkt. cap
7.14B
Avg. vol.
1.28M
Volume
0.00
P/E ratio
138.88
52-wk high
$175.77
52-wk low
$100.99
EPS
$0.91
Beta
1.09
Shares outstanding
56.41M
No. of employees
2K
Analyst outlook
Analyst Ratings
Based on 15 analysts giving stock ratings to RGEN in the past 3 months
Strong Buy
Buy
12
Hold
3
Sell
0
12 month forecast
Based on 15 Wall Street analysts offering 12 month price targets for RGEN in the last 3 months.
Highest
Current $126.55
$208.00 (+64.36%)
Average
$165.17 (+30.52%)
Lowest
$140.00 (+10.63%)
News stories
From sources across the web
Profile
Repligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN. Wikipedia
About Repligen Corp
CEOTony J. Hunt
Employees2K
Founded1981
HeadquartersWaltham, Massachusetts, United States
SectorHealth care
Websiterepligen.com
Last report
May 5, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$0.48 / $0.39
+22.87%beat
Revenue / Est. (USD)
194.26M / 192.35M
+0.99%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
182.37M
188.80M
197.91M
194.26M
Cost of goods sold
89.37M
88.29M
94.08M
85.97M
Cost of revenue
89.37M
88.29M
94.08M
85.97M
Research and development expenses
13.97M
14.18M
13.12M
14.46M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
69.41M
73.66M
74.36M
76.54M
Operating expense
83.38M
87.84M
87.48M
90.99M
Total operating expenses
172.75M
176.13M
181.56M
176.96M
Operating income
9.62M
12.68M
16.35M
17.29M
Other non operating income
3.50M
-446.00K
-11.48M
-750.00K
EBT including unusual items
18.22M
17.11M
19.11M
1.77M
EBT excluding unusual items
13.94M
12.96M
17.59M
16.88M
Income tax expense
3.35M
2.20M
5.83M
-6.56M
Effective tax rate
18.39%
12.86%
30.48%
-370.26%
Other operating expenses
-
-
-
-
Net income
14.87M
14.91M
13.29M
8.33M
Net profit margin
8.15%
7.90%
6.71%
4.29%
Earnings per share
0.37
0.46
0.49
0.48
Interest and investment income
6.58M
6.92M
6.75M
6.34M
Interest expense
-5.77M
-5.83M
-5.91M
-6.00M
Net interest expenses
817.00K
1.09M
842.00K
345.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
29.70M
32.69M
36.30M
37.05M
Gain or loss from assets sale
2.16M
-3.38M
-
13.76M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer